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bstract
The aim of this review was to assess the value of NSAIDs and paracetamol in patients with cancer pain to update a previous review
erformed ten years ago on this topic. The approach was analytic and based on clinical considerations, rather than on raw evidence, which
ften does not provide useful information in clinical practice. Both published reports from an extensive search of electronic data bases were
ollected from January 2001 to December 2011. A free-text search method was used including the following words and their combination:
Anti-inflammatory drugs OR paracetamol OR acetaminophen” AND/OR “cancer pain”. Any randomized-controlled trial was considered.
Thirteen reports fulfitted inclusion criteria in this systematic review. Randomized trials have been performed by using different modalities
f intervention. Single drugs added on opioid therapy or during opioid substitution with opioids as rescue drugs through a patient controlled
nalgesia, were compared with placebo or between them. Five studies regarded paracetamol. Other four studies assessed the efficacy dipyrone,
etorolac, dexketoprofen, and subcutaneous ketoprofen in cancer pain management, mainly on top of an opioid regimen. The role of paracetamol
nd NSAIDs in the management of cancer pain still remains controversial. The papers published in this last decade were unable to answer
he main questions. There is no proof that they should be used to start the treatment and how long they should be administered when opioid
reatment is added on top. While paracetamol seems to be devoid of any benefit, particularly if given at usual clinical doses which should
e less than 4 g/day, ketorolac seems to provide an additive analgesic effect even in patients receiving different doses of opioids. The main
ndication from the analysis of these data is that NSAIDs could be given in patients receiving opioids, evaluating their benefit and weight on
pioid therapy in individual patients who have a favorable response to justify a prolonged use.
 2013 Elsevier Ireland Ltd. All rights reserved.Please cite this article in press as: Mercadante S, Giarratano A. The long a
cetamol in cancer pain management: A critical review. Crit Rev Oncol/He
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.  Introduction
According to the World Health Organization (WHO), non
teroidal anti-inflammatory drugs (NSAIDs) and paraceta-
ol (PAR) are prescribed alone as first step, or in association
o opioids for the subsequent analgesic ladder steps [1]. The
ationale for adding this class of drugs to an opioid regi-
en is to improve the balance between analgesia and adverse
ffects by either increasing analgesia without adding adverse
ffects or by maintaining analgesia with less adverse effects,
roviding an opioid-sparing effect. Concerns about NSAIDs
re related to their adverse effects and the use of this class
f drugs remains debatable, particularly when they are used
rst, and then continued with opioids in the other steps in the
ong-term treatment, when their efficacy cannot be evaluated
ue to the analgesic covering offered by opioids, or in elderly
2]. Evidence-based reviews often provide raw data which do
ot seem always applicable in the clinical setting due to the
igid criteria of selection. For example, conclusions suggest-
ng to increase the dose of NSAIDs to a maximum acceptable
ose [3] may be not advisable from a clinical point of view.
oreover, these reviews focused on the level of methodol-
gy [4], rather than the clinical rationale of the study, which
s fundamental for a consequent clinical application in daily
ractice. Finally, many studies reviewed were really old in
erms of methodology, questions posed, and drugs used. The
im of this review was to assess the value of NSAIDs and
aracetamol in patients with cancer pain to update a previ-
us review performed ten years ago on this topic [5]. The
pproach was analytic and based on clinical considerations,
ather than on raw evidence, which often does not provide
seful information in clinical practice (Tables 1 and 2).Please cite this article in press as: Mercadante S, Giarratano A. The long a
cetamol in cancer pain management: A critical review. Crit Rev Oncol/He
. Methods
Both published reports from an extensive search of




tudies of paracetamol. R (randomized), DB (double blind), CO (crossover), P (par
uthors No. Design Drug - doses 
xelsson (2003) 30 DB CO
7 days
Paracetamol 4 g versus Placebo 
tockler (2004) 30 DB CO
2 days
Paracetamol 5 g versus Placebo 
asmacouglu (2009) 43 DB P
24 h
Paracetamol 4 g
Morphine PCA versus Placebo
Morphine PCA
srael (2010) 22 DB CO
4 days
Paracetamol 2g versus Placebo 
ubero (2010) 50 DB P
7 days
Paracetamol 1.5 g versus Placebo Oncology/Hematology xxx (2013) xxx–xxx
ANCERLIT, and EMBASE were collected from January
001 to December 2011. A free-text search method was used
ncluding the following words and their combination: “Anti-
nflammatory drugs OR paracetamol OR acetaminophen”
ND/OR “cancer pain”. Hand searching of relevant journals,
nd European conference proceedings were also considered.
he references of all relevant reports and review articles
ere searched for additional trials. The inclusion criteria was
andomized-controlled trial performed in cancer patients.
. Results
The literature search retrieved 3703 papers. All abstracts
ere read by the authors and thirteen reports fulfitted inclu-
ion criteria in this systematic review. Four papers were
ot considered, as paracetamol was used in combination
ith hydrocodone and compared with tramadol [6], in
ombination with codeine and compared with hydrocodone-
aracetamol [7], and in combination with oxycodone and
ompared with placebo in patients who were receiving dis-
rete doses of transdermal fentanyl or morphine [8], and
n another study ibuprofen was included in a compound
ontaining cobrotoxin and tramadol [9]. Randomized trials
ave been performed by using different modalities of inter-
ention. Single drugs added on opioid therapy or during
pioid substitution with opioids as rescue drugs through a
atient controlled analgesia, were compared with placebo or
etween them. Five studies regarded paracetamol. Other four
tudies assessed the efficacy dipyrone, ketorolac, dexketopro-
en, subcutaneous ketoprofen, in cancer pain management,
ainly on top of an opioid regimen.nd winding road of non steroidal antinflammatory drugs and para-
matol (2013), http://dx.doi.org/10.1016/j.critrevonc.2013.01.001
. Discussion
In a previous review updated to 2001, the evidence from
linical trials available at that time was of limited amount and
allel).
Results Comments
No differences in pain
intensity
Pain level too low
High doses of paracetamol
Significant differences in pain
intensity
High doses of paracetamol
Differences clinically not
significant
No differences in opioid
consumption or pain intensity
High doses of paracetamol
No differences in pain
intensity
Pain was already controlled with
mean doses of 255 mg of oral
morphine
 No benefit in analgesia or
time to stabilization
Add-on opioid switching to
methadone. No data on final
doses of methadone
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Table 2
Studies of NSAIds. R (randomized), DB (double blind), CO (crossover), P (parallel).
Authors No. Design Drug - doses Results Comments
Duarte (2007) 34 R DB CO
2 days
Dipyrone 2 g versus Placebo Better pain control with
dipyrone
Patients receiving 60 mg of oral
morphine
Pain remained uncontrolled and
placebo phase after crossing-over
was better
Mercadante (2002) 47 R P
4 weeks




Patients receiving morphine in
escalating doses
Rodriguez (2003) 115 R DB P
7 days




Pts with bone pain
Unclear opioid consumption (use of
an integrated score)
Moselli (2010) 172 Semi C
4 weeks
Ketoprofen 700–1400 mg added
to SC morphine versus SC
Better pain control and
less opioid consumption
Dose increments proportional to pain




































































uality. NSAIDs could not be considered analgesics for a spe-
ific type or cause of pain, but may provide additive analgesia
n patients receiving opioids. The simple finding of an opioid
paring effect may be questioned in cancer pain treatment and
hould not merely be an indication to add NSAIDs to an opi-
id regimen, as the same level of analgesia can be achieved
ncreasing opioid dose. It could be questioned whether the
ddiction of NSAIDs to a therapeutic regime is worth expos-
ng the patients to the side effects of another medication,
lthough the use of NSAIDs may be useful when the increases
n opioid dosage determine the occurrence of opioid toxicity
n individuals presenting a significant analgesic response [5].
From the analytical revision of the selected papers in
he last ten years, many flaws were noticed regarding the
ethodology and design chosen by authors to demonstrate
 construct to transfer in clinical practice. Therefore, limited
nformation was added to literature to provide specific guide-
ines.
.1. Paracetamol
Paracetamol is considered a safer non opioid analgesic
n comparison with NSAIDs, and is considered the first
hoice in many guidelines for the management of non cancer
ain [10,11]. However, its efficacy in cancer patients often
eceiving oioids for their background analgesia should be
emonstrated and has been the subject of research in this
ast decade only in a few studies. A randomized double-blind
ross-over placebo-controlled trial was performed to ascer-
ain whether paracetamol has a clinically significant additive
nalgesic effect to morphine in 30 advanced cancer patients
ith well-controlled pain [12]. Patients received paracetamol
000 mg or placebo four times a day for a week. The follow-
ng week patients crossed over to receive the other treatment.Please cite this article in press as: Mercadante S, Giarratano A. The long a
cetamol in cancer pain management: A critical review. Crit Rev Oncol/He
hirty patients receiving a median dose of oral morphine of
0 mg completed both the study weeks. No differences in
ain level between the week with paracetamol and the week
ith placebo could be detected. However, patients included
o
t
obased on contraindications to
NSAIDs.
n the study had a median pain level of 2/10 on a numerical
cale of 0–10. With this level of pain it is quite difficult to
bserve any differences because of a floor effect. Data remain
nconclusive, as the analgesic effect of paracetamol was not
xplored in patients with pain, because patients already had
n optimal pain control, and opioid consumption, for exam-
le a reduction in doses, during the study weeks was not
eported. Finally paracetamol doses proposed seem to be rel-
tively high, particularly for patients at high risks and this
se cannot advised in clinical practice.
In a small double-blind randomized crossover study, para-
etamol was administered in doses of 1 g every 4 h five times
er day (5 g/day), for two days in 30 patients receiving mean
oses of oral morphine equivalents of 200 mg/day and having
oderate pain (4/10 on a numerical scale 0–10) [13]. While
ignificant, the differences in pain intensity were very low
0.4 for the numerical scale 0–10), in patients receiving para-
etamol, although authors report that some patients could
enefit a lot. No differences in preference, breakthrough
oses or adverse effects were reported. The positive inter-
retation is against clinical observations which have shown
hat, on average, a reduction of approximately two points
r a reduction of approximately 30% in the pain intensity
epresent a clinically important difference [14]. Also, the
odalities and doses of paracetamol were of concern (every
our hours five times per day), the nightly dose being skipped,
eaving the patient devoid of the potential analgesic effect of
aracetamol for sleeping hours. A two days study is probably
nsufficient to test an analgesic effect in chronic pain. Finally,
aracetamol doses exceeding 4 g/day are problematic for the
isk of hepatic damage in a population at risk such as elderly
ancer patients.
For instance, these data were contradicted by other studies.
n a pain clinic, 43 patients with non-neuropathic pain who
ere receiving step 2 treatment and having a pain intensitynd winding road of non steroidal antinflammatory drugs and para-
matol (2013), http://dx.doi.org/10.1016/j.critrevonc.2013.01.001
f ≥4/10 were selected for a randomized double-blind con-
rolled study. They received 1 g of paracetamol intravenously
r saline every 6 h. A patient-controlled analgesia with
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ntravenous morphine was offered with a bolus dose of 1 mg
nd a locking time of 5 min [15]. Pain intensity decreased
n both groups, but no significant differences were found
etween the groups. Similarly, no differences in morphine
onsumption were observed. It is likely that this use of
orphine would have flattened any possible influence of
aracetamol. Thus, despite its favorable safety, intravenous
dministration of paracetamol (4 g/day) did not add any ben-
fit over the control of cancer pain in terms of increate in
nalgesic efficacy or decrease in morphine consumption.
In a randomized double-blind, placebo-controlled, cross-
ver trial the adjuntive use of paracetamol with strong opioids
as assessed. Patients receiving a median dose of 255 mg of
ral morphine equivalents, were treated with 500 mg of para-
etamol four times daily for five days and five days with
lacebo in a randomized order. 22 patients concluded the
tudy. No statistically differences in pain intensity (mean dif-
erence 0.16 on a numerical scale 0–10) and breakthrough
nalgesics, as well intensity of adverse effects, were observed
16]. However, patients had a relatively well controlled pain,
nd a floor effect could have minimized the additive analgesic
ffect.
Finally, paracetamol was used to assist opioid switching
rom morphine to methadone in a randomized, double-
lind, placebo-controlled study [17]. Whatever the reason for
witching, possibly uncontrolled pain and/or adverse effects,
0 patients having unfavorable balance between pain and
dverse effects, did not changed their analgesic regimen for
ne week. Observing a patient in a critical situation of poor
nalgesia and adverse effects, without any therapeutic inter-
ention for one week is unrealistic in the real world The
ddition of paracetamol, 750 mg every 6 h for a seven days
eriod, did not provide any benefit in pain control or time of
tabilization of analgesia once methadone was introduced. It
ould have been interesting to know the doses of methadone
chieved in the two groups at time of stabilization, and how
he doses were changed during the study period after starting
ith an inversely proportional ratios used for switching from
orphine to methadone.
.2.  NSAIDs
Despite the large availability of this class of drugs in the
arket, including the new generation of COXIBs, only few
tudies assessed the efficacy of these drugs in cancer pain.
hirty-four ambulatory patients starting 60 mg/day of oral
orphine for cancer pain were randomized to receive in a
ouble-blind, cross-over study design, dipyrone in doses of
00 mg orally every 6 h or placebo. After two days patients
eceived the alternative treatment, while maintaining the
ame dose of morphine. Pain was still uncontrolled (7 and
.5 on a numerical scale, respectively), despite pain controlPlease cite this article in press as: Mercadante S, Giarratano A. The long a
cetamol in cancer pain management: A critical review. Crit Rev Oncol/He
as significantly better with dipyrone [18]. However, after
rossing-over patients switched on placebo seemed to have
 better pain relief in the subsequent two days. Curiously,




a Oncology/Hematology xxx (2013) xxx–xxx
uring the placebo phase, after discontinuation of dipyrone,
s it would provide prolonged analgesia. A correct interpre-
ation should be that in the second phase placebo was as least
s effective as the active drug.
Ketorolac 60 mg/day was given in addition to patients
eceiving different doses of morphine in a randomized con-
rolled study. 47 patients were titrated with oral morphine
ntil achieving adequate analgesia. Subsequently, they were
andomized to receive ketorolac or not and they could change
oses of morphine according to the clinical needs. After
 week patients receiving ketorolac showed a better anal-
esia in comparison with the group of patients receiving
ral morphine only. Morphine dose escalation was lower in
atients treated with ketorolac and an opioid sparing effect
as observed. The use of ketorolac was associated with more
astric discomfort but less constipation and was more con-
enient in a pharmacologic analysis when added to higher
oses of morphine [19]. While this study demonstrated that
etorolac produced a significant analgesic effect indepen-
ently from the doses of morphine, data on long-term use
re lacking.
115 patients with bone cancer pain were randomized for a
ouble-blind evaluation of short-term (7 days) analgesic effi-
acy of dexketoprofen 25 mg or ketorolac 10 mg every 6 h.
he treatments were comparable [20]. A pain rating index of
10, calculated from intensity and frequency of pain, anal-
esic taken, incapacity due to pain, sleep disturbances, and
 pain intensity of ≥4/10 on a numerical scale 0 to 10, were
sed as inclusion criteria, so that it was impossible to know
he real opioid consumption.
With regard to the route of administration, when the
ral route is impracticable, continuous subcutaneous infu-
ion (CSI) is considered as an effective, simple and cheap
lternative. In a prospective observational open-label study,
atients with severe pain receiving more than 240 mg of oral
orphine equivalents, or patients who failed adequate trials
f other strong opioids were treated with a continuous infu-
ion of CSI of ketoprofen added to CSI of morphine [21].
his group of patients was also compared with a concomitant
roup of patients treated with a CSI of morphine only, because
f existing contraindications to NSAIDs. Patients were first
onverted from oral opioids to CSI of morphine, eventu-
lly increasing the dosage by 25–50% in case of severe pain
7–8/10 and 9–10/10 on a numerical scale, respectively). The
ose of ketoprofen was 700 or 1400 mg/day in patients with
 pain intensity of 7–8/10 or 9–10/10, respectively and dose
f morphine was reduced by 10% to potentially counterbal-
nce the ketoprofen additive analgesic effect. Thus, authors
ssumed that doses could be proportional to the high levels of
he numerical scale, as it would be a linear relation between
n increase in opioid dose and the analgesic effect of the drug.
ubsequently the CSI morphine dose were proportionallynd winding road of non steroidal antinflammatory drugs and para-
matol (2013), http://dx.doi.org/10.1016/j.critrevonc.2013.01.001
hanged weekly according to the pain severity or the number
f boluses of CSI morphine used as breakthrough pain medi-
ation. From a large number of patients who underwent CSI,
uthors analyzed data regarding patients with a follow-up of
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t least one month, 172 receiving morphine ketoprofen CSI
nd 48 patients receiving morphine CSI only. In the efficacy
nalysis authors included patients with well controlled pain
hen they had a pain intensity of 0–2/10. This in contrast
ith data which indicated a different cut-off to define mild
ain, which is acceptable, generally not requiring changes
n opioid doses [22]. The opioid consumption seemed to be
uperior in patients treated without ketoprofen in comparison
ith patients receiving the CSI with the drug-combination.
nly a minority of patients (2.3%) discontinued ketoprofen
ue to adverse effects. This was a non randomized controlled
tudy with clear differences of group samples. Data were also
ifficult to interpret given the rationale of the study protocol
hich suggested to use increments strictly related to numer-
cal scale numbers. Also, one should argue from the protocol
hat a level of 6/10 of pain intensity is considered to be a
easonable goal, as dose increments are proposed only when
ain intensity get severe (≥7/10). However pain intensity of
–6/10 (moderate pain) is estimated to significantly inter-
ere with the quality of patients’ life [22], and generally the
onsequent action is to change the opioid dose.
. Conclusion
The role of paracetamol and NSAIDs in the management
f cancer pain still remains controversial. The question on
ow and when using these drugs has not been resolved. The
apers published in this last decade were unable to answer the
ain questions. There is no proof that they should be used to
tart the treatment and how long they should be administered
hen opioid treatment is added on top. Paracetamol seems to
e devoid of any benefit, particularly if given at usual clinical
oses of less than 4 g/day. Indeed, ketorolac seems to provide
n additive analgesic effect even in patients receiving differ-
nt doses of opioids. The main suggestion from the analysis
f these data is that NSAIDs could be given in patients receiv-
ng opioids and evaluating their benefit and weight on opioid
herapy in individual patients who have a favorable response
o justify a prolonged use. No proof has been provided about
he use of this class of drugs as first step of the analgesic
adder.
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